A promising strategy change for the pharmaceutical Biovail
Home » Media Mentions » A promising strategy change for the pharmaceutical Biovail
April 4, 2009
The revival of the pharmaceutical company Biovail (Tor., BVF, $ 13.07) is on track and could offer a good investment opportunity, according to some financial.
Claret Asset Management specializes in offering portfolio management services to high net worth clients. We are completely independent and free of conflicts of interest. Claret was founded in 1996 with the objective of answering the growing needs of private investors.